Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794104 · ClinicalTrials.gov registry record · Phase 1
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01794104: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01794104 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01794104, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Background: \- Indenoisoquinoline LMP400 is an experimental cancer treatment drug. It damages DNA in tumor cells. Tumor cells with damaged DNA may die, resulting in cell death. Researchers want to see if this drug is a safe and effective treatment for solid tumors and lymphomas that have not responded to earlier treatment. Objectives: \- To see if Indenoisoquinoline LMP400 is a safe and effective treatment for advanced solid tumors or lymphomas. Eligibility: \- Individuals at least 18 years of age who have solid tumors or lymphomas that have not responded to treatment. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Tumor samples may also be collected. The size and location of the tumors will be determined with imaging studies. * Indenoisoquinoline LMP400 is given in a 28-day cycle. Participants will receive the drug by intravenous infusion on days 1, 8, and 15 of each cycle, followed by a break of 13 days without the drug. * Treatment will be monitored with frequent blood tests and imaging studies. Tumor samples will be optional. * Participants will continue their cycles of treatment as long as the cancer does not grow and there are no severe side effects.
Interventions
- DRUG LMP400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-02-15 |
| Est. Completion | 2017-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794104
The ClinicalTrials.gov registry entry for NCT01794104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LMP400 is the first listed.
NCT01794104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01794104 about?
NCT01794104 is a clinical study titled "Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas". Background: \- Indenoisoquinoline LMP400 is an experimental cancer treatment drug. It damages DNA in tumor cells. Tumor cells with damaged DNA may die, resulting in cell death. Researchers want to see if this drug is a safe and effective treatment for solid tumors and lymphomas that have not respon...
What is the current status of trial NCT01794104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2013-02-15. Estimated completion is 2017-10-27.
What interventions are being tested in trial NCT01794104?
The interventions under investigation include: LMP400 (DRUG).
Who is sponsoring clinical trial NCT01794104?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.